Investors

Press Releases

Press Releases

November 8, 2018
-- Clinical data expected in early first quarter 2019 -- SAN CARLOS, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced
August 29, 2018

SAN CARLOS, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced financial results for the second quarter ended June 30,

July 19, 2018

SAN CARLOS, Calif. , July 19, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. , (Nasdaq:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various eosinophil and mast cell related diseases, today announced the pricing of its initial public offering of

Copyright West LLC. Minimum 15 minutes delayed.